Abstract

We aimed to investigate metabolites associated with the 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) in patients with rheumatoid arthritis (RA) using capillary electrophoresis quadrupole time-of-flight mass spectrometry. Plasma and urine samples were collected from 32 patients with active RA (DAS28-ESR≥3.2) and 17 with inactive RA (DAS28-ESR<3.2). We found 15 metabolites in plasma and 20 metabolites in urine which showed a significant but weak positive or negative correlation with DAS28-ESR. When metabolites between active and inactive patients were compared, 9 metabolites in plasma and 15 in urine were found to be significantly different. Consequently, we selected 11 metabolites in plasma and urine as biomarker candidates which significantly correlated positively or negatively with DAS28-ESR, and significantly differed between active and inactive patients. When a multiple logistic regression model was built to discriminate active and inactive cohorts, three variables—histidine and guanidoacetic acid from plasma and hypotaurine from urine—generated a high area under the receiver operating characteristic (ROC) curve value (AUC = 0.8934). Thus, this metabolomics approach appeared to be useful for investigating biomarkers of RA. Combination of plasma and urine analysis may lead to more precise and reliable understanding of the disease condition. We also considered the pathophysiological significance of the found biomarker candidates.

Highlights

  • Rheumatoid arthritis (RA) is a systemic autoimmune disease which involves inflammation of the synovium and destruction of joint cartilage and bone [1,2]

  • Most RA patients had been treated with methotrexates and/or glucocorticoids, and none had been treated with biologics

  • Since ketoprofen found in urine was an exogenous metabolite, we excluded it from the following analysis

Read more

Summary

Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease which involves inflammation of the synovium and destruction of joint cartilage and bone [1,2]. Metabolomic approach for RA disease activity biomarkers following competing interests: CS, TH, TO, KO, KS, IA and YH are employees of Astellas Pharma Inc. MH received research grant and/or speaker fee from Astellas Pharma Inc, Eisai Co. Ltd., Mitsubishi Tanabe Pharma Co., and Brystol-Meyers Squibb Co., Ltd., for other unrelated work. This does not alter our adherence to PLOS ONE policies on sharing data and materials

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call